1. Inici
  2. Publicacions
  3. Role of capsule endoscopy in suspected celiac disease: A European multi-centre study

Role of capsule endoscopy in suspected celiac disease: A European multi-centre study

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Lujan-Sanchis, M
  • Perez-Cuadrado-Robles, E
  • Garcia-Lledo, J
  • Juanmartiñena Fernández JF
  • Elli, L
  • Jimenez-Garcia, VA
  • Egea-Valenzuela, J
  • Valle-Munoz, J
  • Carretero-Ribon, C
  • Fernandez-Urien-Sainz, I
  • Lopez-Higueras, A
  • Sanjuan-Acosta, M
  • Sanchez-Ceballos, F
  • Rosa, B
  • Gonzalez-Vazquez, S
  • Branchi, F
  • Ruano-Diaz, L
  • Prieto-de-Frias, C
  • Gonzalez-Suarez, B
  • Xavier, S
  • Arguelles-Arias, F
  • Herrerias-Gutierrez, JM
  • Perez-Cuadrado-Martinez, E
  • Sempere-Garcia-Arguelles, J

Grups d'Investigació

Abstract

AIM To analyze the diagnostic yield (DY), therapeutic impact (TI) and safety of capsule endoscopy (CE). METHODS This is a multi-centre, observational, analytical, retrospective study. A total of 163 patients with suspicion of celiac disease (CD) (mean age = 46.4 +/- 17.3 years, 68.1% women) who underwent CE from 2003 to 2015 were included. Patients were divided into four groups: seronegative CD with atrophy (Group-I n = 19), seropositive CD without atrophy (Group-II, n = 39), contraindication to gastroscopy (Group-III, n = 6), seronegative CD without atrophy, but with a compatible context (Group-IV, n = 99). DY, TI and the safety of CE were analysed. RESULTS The overall DY was 54% and the final diagnosis was villous atrophy (n = 65, 39.9%), complicated CD (n = 12, 7.4%) and other enteropathies (n = 11, 6.8%; 8 Crohn's). DY for groups I to IV was 73.7%, 69.2%, 50% and 44.4%, respectively. Atrophy was located in duodenum in 24 cases (36.9%), diffuse in 19 (29.2%), jejunal in 11 (16.9%), and patchy in 10 cases (15.4%). Factors associated with a greater DY were positive serology (68.3% vs 49.2%, P = 0.034) and older age (P = 0.008). On the other hand, neither sex nor clinical presentation, family background, positive histology or HLA status were associated with DY. CE results changed the therapeutic approach in 71.8% of the cases. Atrophy was associated with a greater TI (92.3% vs 45.3%, P < 0.001) and 81.9% of the patients responded to diet. There was one case of capsule retention (0.6%). Agreement between CE findings and subsequent histology was 100% for diagnosing normal/other conditions, 70% for suspected CD and 50% for complicated CD. CONCLUSION CE has a high DY in cases of suspicion of CD and it leads to changes in the clinical course of the disease. CE is safe procedure with a high degree of concordance with histology and it helps in the differential diagnosis of CD.

Dades de la publicació

ISSN/ISSNe:
1007-9327, 2219-2840

WORLD JOURNAL OF GASTROENTEROLOGY  BAISHIDENG PUBLISHING GROUP INC

Tipus:
Article
Pàgines:
703-711
PubMed:
28216978
Factor d'Impacte:
1,409 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 20

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Capsule endoscopy; Celiac disease; Anti-transglutaminase antibodies; Gluten-free diet; Non-celiac gluten sensitivity

Campos d'Estudi

Projectes associats

RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010

WIBEC. WIRELESS IN-BODY ENVIRONMENT COMMUNICATIONS.

Investigador Principal: VICENTE PONS BELTRÁN

675353 . COMISION EUROPEA . 2016

ESTUDIO DE FASE III, ALEATORIZADO, A DOBLE CIEGO, CONTROLADO CON PLACEBO SOBRE TERAPIA ADYUVANTE CON VEMURAFENIB (RO5185426) EN PACIENTES CON MELANOMA CUTÁNEO CON MUTACIÓN DE BRAF RESECADO QUIRÚRGICAMENTE CON ALTO RIESGO DE RECIDIVA.

Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE

GO27826 . 2013

ESTUDIO ALEATORIZADO Y ABIERTO, PARA COMPARAR DURANTE 26 SEMANAS EL EFECTO DEL TRATAMIENTO CON GEL INTESTINAL DE LEVODOPA-CARBIDOPA (GILC) Y DEL TRATAMIENTO MÉDICO ÓPTIMO (TMO) SOBRE LOS SÍNTOMAS NO MOTORES (SNM) EN PACIENTES CON ENFERMEDAD DE PARKINSON AVANZADA - ESTUDIO INSIGHTS.

Investigador Principal: IRENE MARTÍNEZ TORRES

M12-927 . 2015

IMPACTO DE LA PAPILOTOMIA DURANTE LA COLANGIOPANCREATOGRAFÍA RETRÓGRADA ENDOSCÓPICA (CPRE) PARA LA IMPLANTACION DE UN STENT BILIAR METALICO NO CUBIERTOEN PACIENTES CON ICTERICIA OBSTRUCTIVA POR TUMORES MALIGNOS DE PANCREAS

Investigador Principal: VICENTE PONS BELTRÁN

PAP-ADE-01

ESTUDIO ALEATORIZADO, ENMASCARADO, CONTROLADO CON PLACEBO SOBRE LOS EFECTOS DE ADALIMUMAB INTRALESIONAL EN ESTENOSIS INTESTINALES DE PACIENTES CON ENFERMEDAD DE CROHN.

Investigador Principal: LIDIA ARGÜELLO VIUDEZ

CSAI

ENSAYO FASE 2A PARA EVALUAR LA EFICACIA Y SEGURIDAD DE MEDI2070 EN PACIENTES CON ENFERMEDAD DE CROHN MODERADA A GRAVE QUE NO HAN RESPONDIDO O NO TOLERAN LA TERAPIA CON ANTIFACTOR DE NECROSIS TUMORAL ALFA.

Investigador Principal: GUILLERMO BASTIDA PAZ

CD-IA-MEDI2070-1147/D5170C00001

Compartir la publicació